Related Experiment Video
Updated: Aug 6, 2026
Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
Published on: December 1, 2023
Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis - an observational study
Joanna Rychter1, Aleksandra Podlecka-Piętowska2, Kinga Sujkowska1
1Department of Neurology, Medical University of Warsaw, Poland.
Introduction:
Anti-CD20 monoclonal antibodies are widely used as high-efficacy treatment agents (HETAs) in multiple sclerosis (MS). In patients treated with ocrelizumab (OCR), reduced serum IgG levels are a common laboratory abnormality. Infections are among the most frequently observed adverse events during OCR therapy.
Material And Methods:
We analyzed the humoral immune response during OCR therapy in 52 people with multiple sclerosis (PwMS) and assessed the safety of this treatment, including treatment-related adverse events and infection rates over a period of up to six years.
Results:
After three years of treatment, immunoglobulin G (IgG) and IgG1 levels decreased, particularly in the relapsing-remitting MS (RMS) group. Higher body mass index (BMI) was associated with lower Ig levels and greater CD19+ cell depletion. Infections were more frequent in patients with relapses within 3 months prior to OCR initiation. Clinical implications/future directions. Ocrelizumab treatment for up to six years showed a manageable safety profile. Given the higher infection risk in patients with greater disease activity, earlier HETA initiation may be beneficial. The association between higher BMI and CD19+ cell depletion warrants further study to support personalized OCR dosing strategies.
